Report of Foreign Issuer (6-k)
August 10 2017 - 3:37PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO
RULE 13A-16 OR 15D-16
UNDER THE
SECURITIES EXCHANGE ACT OF 1934
Dated August 10, 2017
Commission File
Number 001-36421
AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrants Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250)
708-4272
(Address and telephone number of registrants principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F or
Form 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting the
Form 6-K in
paper as permitted by
Regulation S-T Rule
101(b) (1): ☐
Indicate by check mark if the
registrant is submitting the
Form 6-K in
paper as permitted by
Regulation S-T Rule
101(b) (7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☒ No ☐
This Form
6-K
is hereby filed and incorporated by reference in the registrants Registration
Statement on Form
F-10
(File
No. 333-206994).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Dated: August 10, 2017.
|
|
|
|
|
Aurinia Pharmaceuticals Inc.
|
|
|
By:
|
|
/s/ Dennis Bourgeault
|
|
|
Name:
|
|
Dennis Bourgeault
|
|
|
Title:
|
|
Chief Financial Officer
|
2
EXHIBIT INDEX
|
|
|
Exhibit
|
|
Description of Exhibit
|
|
|
99.1
|
|
Interim Condensed Consolidated Financial Statements for the Second Quarter ended June 30, 2017
|
|
|
99.2
|
|
MD&A for the Second Quarter ended June 30, 2017
|
|
|
99.3
|
|
Certification of Interim Filings Chief Executive Officer
|
|
|
99.4
|
|
Certification of Interim Filings Chief Financial Officer
|
Exhibits 99.1, 99.2, 99.3 and 99.4 included with this report on Form
6-K
are hereby
incorporated by reference as exhibits to the Registration Statement on Form
F-10
of Aurinia Pharmaceuticals Inc. (File
No. 333-206994),
as amended or supplemented.
3
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2024 to May 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2023 to May 2024